Basic Information
| LncRNA/CircRNA Name | DNAH17-AS1 |
| Synonyms | NA |
| Region | GRCh38_17:78484882-78503056 |
| Ensemble | ENSG00000267432 |
| Refseq | NR_102401 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, Western blot, luciferase reporter assay etc. |
| Sample | PC tissue and adjacent normal tissue,cell lines (HPDE6-C7,Hs766T and SW1990) |
| Expression Pattern | up-regulated |
| Function Description | DNAH17-AS1 was upregulated in PC cells and was associated with aggressive tumor behavior and poor prognosis for patients. DNAH17-AS1 served as a PC oncogene by downregulating miR-432-5p which normally directly targeted PPME1 to downregulate its expression. |
| Pubmed ID | 32351291 |
| Year | 2020 |
| Title | DNAH17-AS1 promotes pancreatic carcinoma by increasing PPME1 expression via inhibition of miR-432-5p. |
External Links
| Links for DNAH17-AS1 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |